Compresor Nebulizador AL-50

Información básica

• Disponible en:
• English
• Español

Introducing the EarlyTect Colon Cancer Test, a breakthrough product in the field of colorectal cancer diagnostics. This test has received approval from the Korea Ministry of Food and Drug Safety after rigorous clinical trials conducted at renowned medical centers.

Comprising of clinical trials conducted on 585 eligible subjects, including both men and women aged 30 to 80, the EarlyTect Colon Cancer Test utilizes fecal DNA analysis to achieve an impressive 90% sensitivity and specificity in diagnosing colorectal cancer. By measuring the levels of methylated Syndecan-2, a clinically significant biomarker for precancerous lesions of colorectal cancer, in stool DNA, this qualitative real-time PCR test provides accurate detection and diagnosis.

It is important to note that the EarlyTect Colon Cancer Test is not designed to confirm the presence of colorectal cancer. However, if a subject tests positive for the biomarker, it indicates the possibility of colorectal cancer or precancerous lesions of colorectal cancer. Further medical investigation is required for confirmation.

The product adheres to specific standards and specifications, including:
- Cancer Type: Colorectal Cancer
- Subject: Asymptomatic individuals undergoing colorectal cancer screening
- Biomarker: SDC2 methylation

For pricing and transaction details, we are open to negotiations. Please feel free to request a quote to initiate the transaction process.